Amendments to the Claims

Claim 1 (original) A compound of Formula I:



I

where:

R^1 is $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_1\text{-}C_6$ alkyl), $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_2\text{-}C_6$ alkenyl), $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_2\text{-}C_6$ alkynyl) or $C_3\text{-}C_7$ cycloalkyl, each optionally substituted with up to three groups independently selected from halo, hydroxy, thiol, cyano, trifluoromethyl, trifluoromethoxy, $C_1\text{-}C_7$ alkoxy, $C_3\text{-}C_7$ cycloalkoxy, oxo, and NR^4R^5, biphenyl optionally substituted with halo, hydrogen,  or  ;

R^2 is $C_1\text{-}C_3$ alkyl, benzyl optionally monosubstituted in the phenyl ring with a substituent selected from the group consisting of halo, $C_1\text{-}C_6$ alkoxy optionally substituted in the alkyl chain with $C_3\text{-}C_7$ cycloalkyl, and $C_1\text{-}C_6$ alkylthio optionally substituted in the alkyl chain with $C_3\text{-}C_7$ cycloalkyl, or benzyl optionally disubstituted in the phenyl ring with a first substituent independently selected from halo and a second substituent independently selected from halo, $C_1\text{-}C_6$ alkoxy optionally substituted in the alkyl chain with $C_3\text{-}C_7$ cycloalkyl, and $C_1\text{-}C_6$ alkylthio optionally substituted in the alkyl chain with $C_3\text{-}C_7$ cycloalkyl;

R^3 is:

i) a piperidin-2-yl moiety of formula:



(a) or (b);

ii) a tetrahydropyridin-2-yl moiety of formula:



;

iii) a piperazin-2-yl moiety of formula:



;

iv) homopiperidin-2-yl;

v) 1,2,3,4-tetrahydroisoquinolin-3-yl optionally substituted with one or two substituents selected from halo, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

vi) 2-azabicyclo[2.2.2]oct-(5Z)ene-3-yl;

vii) 2-azabicyclo[2.2.1]hept-3-yl optionally substituted with C_1-C_{10} alkyl optionally substituted with C_1-C_4 alkoxy; or

viii) 2-azabicyclo[2.2.2]oct-3-yl optionally substituted with oxo, or optionally substituted with one or two substituents independently selected from hydroxy, fluoro, and C_1-C_6 alkyl;

X is CH, N, or N^+-O^-;

Y is CR^{11}, N, or N^+-O^-;

Q is CR^{12}, N, or N^+-O^-;

R^4 is hydrogen, C_1-C_6 alkyl optionally substituted up to three times with fluoro, or phenyl;

R^5 is hydrogen, C_1-C_6 alkyl optionally substituted up to three times with fluoro, phenyl, -C(O)(C_1-C_6 alkyl optionally substituted up to three times with fluoro), or –SO_2(C_1-C_6 alkyl optionally substituted up to three times with fluoro);

R^6 and R^7 are independently selected from the group consisting of methyl, ethyl, and propyl;

R^8 is hydrogen or C_1-C_6 alkyl;

R^9 is C_3-C_5 cycloalkyl, sec-butyl, or –CH_2R^{13};

R^{10} is –CF_2R^{14}, -OR^{15}, -$CH_2C(O)CH_3$, -$S(O)_{1\text{-}2}R^{16}$, -$NR^{17}SO_2R^{18}$, (C_1-C_3 alkoxy)-carbonyl, phenyl optionally substituted with halo, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,1-

dioxo-2,3,4,5-tetrahydroisothiazol-2-yl, or tetrazol-5-yl optionally substituted with C_1-C_3 alkyl;

R^{11} is hydrogen, chloro, isobutyl, CH_2R^{19}; CF_2R^{20}, 1,1,1-trifluoro-2-hydroxyeth-2-yl, C_2-C_4 alkenyl optionally substituted with one or two fluorine atoms, OR^{21}, $C(O)R^{22}$, N(methyl)(methylsulfonyl), N(methyl)(acetyl), pyrrolidin-2-on-1-yl, methylsulfonyl, N,N-dimethylaminosulfonyl, phenyl optionally substituted with one or two substituents selected from the group consisting of hydroxymethyl, methoxy, fluoro, and methylsulfonyl, 1,3-dioxolan-2-yl, 1,3-dithiolan-2-yl, 1,3-oxathiolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithian-2-yl, pyridinyl, thiazolyl, oxazolyl, or 1,2,4-oxadiazolyl optionally substituted with methyl;

R^{12} is hydrogen or fluoro;

R^{13} is ethynyl or cyclopropyl;

R^{14} is hydrogen or methyl;

R^{15} is difluoromethyl or methanesulfonyl;

R^{16} is C_1-C_4 alkyl, C_3-C_6 cycloalkyl, phenyl, or $-NR^{25}R^{26}$;

R^{17} is hydrogen, C_1-C_3 alkyl optionally substituted with up to 3 fluorine atoms, or C_3-C_6 cycloalkyl;

R^{18} is C_1-C_3 alkyl or C_3-C_6 cycloalkyl;

R^{19} is fluoro, hydroxy, or C_1-C_3 alkoxy;

R^{20} is hydrogen, phenyl, or furyl;

R^{21} is C_1-C_3 alkyl optionally substituted with one or two fluorine atoms;

R^{22} is C_1-C_3 alkyl, C_3-C_5 cycloalkyl, C_2-C_3 alkenyl, C_1-C_3 alkoxy, $NR^{23}R^{24}$, pyrrolidin-1-yl optionally substituted with methyl or one or two fluorine atoms, piperidin-1-yl, phenyl, pyridinyl, or furyl;

R^{23} is hydrogen or methyl;

R^{24} is methyl, ethyl, or propyl;

R^{25} is hydrogen or methyl;

R^{26} is methyl; or

R^{25} and R^{26} taken together with the nitrogen atom to which they are attached form a pyrrolidine or piperidine ring;

R^{29} is hydrogen or C_1-C_6 alkyl;

R^{30} is hydrogen or C_1-C_6 alkyl;

R^{29} and R^{30} taken together with the carbon to which they are attached form a C_3-C_6 cycloalkyl ring;

R^{31} is hydrogen, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, or phenyl optionally monosubstituted with C_1-C_6 alkyl;

R^{32} is hydrogen, R^{33}, or $-(CH_2)_{0-2}$-OR^{33};

R^{33} is C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2-C_6 alkenyl, C_2-C_6 alkynyl, or $-(CH_2)_{0-3}$-R^{34};

R^{34} is C_3-C_7 cycloalkyl or phenyl each optionally substituted with one or two substitutents independently selected from the group consisting of halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, thienyl optionally substituted with halo, benzothienyl optionally substituted with halo, thiazolyl optionally substituted with C_1-C_4 alkyl, or adamantyl;

R^{35} is $-(CH_2)_{0-6}$-R^{34},$-C(O)-(CH_2)_{0-6}$-R^{34}, $-C(O)-(C_1$-C_{10} alkyl), $-C(O)-(C_1$-C_4 alkoxy optionally substituted with phenyl), C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2-C_{10} alkenyl, or C_2-C_{10} alkynyl;

R^{36} and R^{37} are both hydrogen or, taken together with the carbon atom to which they are attached form a carbonyl group; or a pharmaceutically acceptable salt thereof; provided that: a) no more than one of X, Y, and Q may be N or N^+-O^-; and b) when X is CH, Y is CR^{11}, and Q is CR^{12}, then one of R^{11} and R^{12} is other than hydrogen.

Claims 2-5 (canceled)

Claim 6 (original): A pharmaceutical formulation comprising a compound of Claim 1, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 7 (original): A compound of Formula III:



III

where:

R^1 is $(C_3$-C_7 cycloalkyl$)_{0-1}(C_1$-C_6 alkyl), $(C_3$-C_7 cycloalkyl$)_{0-1}(C_2$-C_6 alkenyl), $(C_3$-C_7 cycloalkyl$)_{0-1}(C_2$-C_6 alkynyl) or C_3-C_7 cycloalkyl, each optionally substituted with up to three groups independently selected from halo, hydroxy, thiol, cyano, trifluoromethyl,

trifluoromethoxy, C_1-C_7 alkoxy, C_3-C_7 cycloalkoxy, oxo, and NR^4R^5, biphenyl optionally substituted with halo, hydrogen,



or



;

R^2 is C_1-C_3 alkyl, benzyl optionally monosubstituted in the phenyl ring with a substituent selected from the group consisting of halo, C_1-C_6 alkoxy optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, and C_1-C_6 alkylthio optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, or benzyl optionally disubstituted in the phenyl ring with a first substituent independently selected from halo and a second substituent independently selected from halo, C_1-C_6 alkoxy optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, and C_1-C_6 alkylthio optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl;

$R^{3'}$ is:

ix) a piperidin-2-yl moiety of formula:



(f)

or



(g) ;

x) a tetrahydropyridin-2-yl moiety of formula:



(h)

or



(j) ;

xi) a piperazin-2-yl moiety of formula:



(k) ;

xii) homopiperidin-2-yl substituted in the 1-position with variable R^{28};

xiii) 1,2,3,4-tetrahydroisoquinolin-3-yl substituted in the 1-position with variable R^{28} and optionally further substituted with one or two substituents selected from halo, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

xiv) 2-azabicyclo[2.2.2]oct-(5Z)ene-3-yl substituted in the 2-position with variable R^{28};

xv) 2-azabicyclo[2.2.1]hept-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with C_1-C_{10} alkyl optionally substituted with C_1-C_4 alkoxy; or

xvi) 2-azabicyclo[2.2.2]oct-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with oxo, or optionally further substituted with one or two substituents independently selected from hydroxy, fluoro, and C_1-C_6 alkyl;

X is CH, N, or N^+-O^-;

Y is CR^{11}, N, or N^+-O^-;

Q is CR^{12}, N, or N^+-O^-;

R^4 is hydrogen, C_1-C_6 alkyl optionally substituted up to three times with fluoro, or phenyl;

R^5 is hydrogen, C_1-C_6 alkyl optionally substituted up to three times with fluoro, phenyl, -C(O)(C_1-C_6 alkyl optionally substituted up to three times with fluoro), or –SO_2(C_1-C_6 alkyl optionally substituted up to three times with fluoro);

R^6 and R^7 are independently selected from the group consisting of methyl, ethyl, and propyl;

R^8 is hydrogen or C_1-C_6 alkyl;

R^9 is C_3-C_5 cycloalkyl, sec-butyl, or –CH_2R^{13};

R^{10} is –CF_2R^{14}, -OR^{15}, -$CH_2C(O)CH_3$, -$S(O)_{1\text{-}2}R^{16}$, -$NR^{17}SO_2R^{18}$, (C_1-C_3 alkoxy)-carbonyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,1-dioxo-2,3,4,5-tetrahydroisothiazol-2-yl, or tetrazol-5-yl optionally substituted with C_1-C_3 alkyl;

R^{11} is hydrogen, chloro, isobutyl, CH_2R^{19}; CF_2R^{20}, 1,1,1-trifluoro-2-hydroxyeth-2-yl, C_2-C_4 alkenyl optionally substituted with one or two fluorine atoms, OR^{21}, $C(O)R^{22}$, N(methyl)(methylsulfonyl), N(methyl)(acetyl), pyrrolidin-2-on-1-yl, methylsulfonyl, N,N-dimethylaminosulfonyl, phenyl optionally substituted with one or two substituents selected from the group consisting of hydroxymethyl, methoxy, fluoro, and methylsulfonyl, 1,3-

dioxolan-2-yl, 1,3-dithiolan-2-yl, 1,3-oxathiolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithian-2-yl, pyridinyl, thiazolyl, oxazolyl, or 1,2,4-oxadiazolyl optionally substituted with methyl;

R^{12} is hydrogen or fluoro;

R^{13} is ethynyl or cyclopropyl;

R^{14} is hydrogen or methyl;

R^{15} is difluoromethyl or methanesulfonyl;

R^{16} is C_1-C_4 alkyl, C_3-C_6 cycloalkyl, phenyl, or $-NR^{25}R^{26}$;

R^{17} is hydrogen, C_1-C_3 alkyl optionally substituted with up to 3 fluorine atoms, or C_3-C_6 cycloalkyl;

R^{18} is C_1-C_3 alkyl or C_3-C_6 cycloalkyl;

R^{19} is fluoro, hydroxy, or C_1-C_3 alkoxy;

R^{20} is hydrogen, phenyl, or furyl;

R^{21} is C_1-C_3 alkyl optionally substituted with one or two fluorine atoms;

R^{22} is C_1-C_3 alkyl, C_3-C_5 cycloalkyl, C_2-C_3 alkenyl, C_1-C_3 alkoxy, $NR^{23}R^{24}$, pyrrolidin-1-yl optionally substituted with methyl or one or two fluorine atoms, piperidin-1-yl, phenyl, pyridinyl, or furyl;

R^{23} is hydrogen or methyl;

R^{24} is methyl, ethyl, or propyl;

R^{25} is hydrogen or methyl;

R^{26} is methyl; or

R^{25} and R^{26} taken together with the nitrogen atom to which they are attached form a pyrrolidine or piperidine ring;

R^{27} is hydrogen or a nitrogen protecting group;

R^{28} is hydrogen or a nitrogen protecting group;

R^{29} is hydrogen or C_1-C_6 alkyl;

R^{30} is hydrogen or C_1-C_6 alkyl;

R^{29} and R^{30} taken together with the nitrogen to which they are attached form a C_3-C_6 cycloalkyl ring;

R^{31} is hydrogen, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, or phenyl optionally monosubstituted with C_1-C_6 alkyl;

R^{32} is hydrogen, R^{33}, or $-(CH_2)_{0\text{-}2}$-OR^{33};

R^{33} is C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2-C_6 alkenyl, C_2-C_6 alkynyl, or $-(CH_2)_{0\text{-}3}$-R^{34};

R^{34} is C_3-C_7 cycloalkyl or phenyl each optionally substituted with one or two substitutents independently selected from the group consisting of halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, thienyl optionally substituted with halo, benzothienyl optionally substituted with halo, thiazolyl optionally substituted with C_1-C_4 alkyl, or adamantyl;

R^{35} is -$(CH_2)_{0-6}$-R^{34},-C(O)-$(CH_2)_{0-6}$-R^{34}, -C(O)-(C_1-C_{10} alkyl), -C(O)-(C_1-C_4 alkoxy optionally substituted with phenyl), C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2-C_{10} alkenyl, or C_2-C_{10} alkynyl;

R^{36} and R^{37} are both hydrogen or, taken together with the carbon atom to which they are attached form a carbonyl group;

R^{38} is hydrogen or an oxygen protecting group; or an acid addition salt thereof provided that: a) no more than one of X, Y, and Q may be N or N^+-O^-; b) when X is CH, Y is CR^{11}, and Q is CR^{12}, then one of R^{11} and R^{12} is other than hydrogen; and c) at least one of R^{27}, R^{28}, and R^{38} is other than hydrogen.

Claim 8 (original): A compound of Formula IV:



IV

where:

R^1 is (C_3-C_7 cycloalkyl)$_{0-1}$(C_1-C_6 alkyl), (C_3-C_7 cycloalkyl)$_{0-1}$(C_2-C_6 alkenyl), (C_3-C_7 cycloalkyl)$_{0-1}$(C_2-C_6 alkynyl) or C_3-C_7 cycloalkyl, each optionally substituted with up to three groups independently selected from halo, hydroxy, thiol, cyano, trifluoromethyl, trifluoromethoxy, C_1-C_7 alkoxy, C_3-C_7 cycloalkoxy, oxo, and NR^4R^5, biphenyl optionally substituted with halo, hydrogen,



or



;

R^2 is C_1-C_3 alkyl, benzyl optionally monosubstituted in the phenyl ring with a substituent selected from the group consisting of halo, C_1-C_6 alkoxy optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, and C_1-C_6 alkylthio optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, or benzyl optionally disubstituted in the phenyl ring with a first substituent independently selected from halo and a second substituent independently selected from halo, C_1-C_6 alkoxy optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, and C_1-C_6 alkylthio optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl;

$R^{3'}$ is:

ix) a piperidin-2-yl moiety of formula:



;

x) a tetrahydropyridin-2-yl moiety of formula:



;

xii) a piperazin-2-yl moiety of formula:



;

xii) homopiperidin-2-yl substituted in the 1-position with variable R^{28};

xiii) 1,2,3,4-tetrahydroisoquinolin-3-yl substituted in the 1-position with variable R^{28} and optionally further substituted with one or two substituents selected from halo, C_1-C_6 alkyl, and C_1-C_6 alkoxy;

xiv) 2-azabicyclo[2.2.2]oct-(5Z)ene-3-yl substituted in the 2-position with variable R^{28};

xv) 2-azabicyclo[2.2.1]hept-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with C_1-C_{10} alkyl optionally substituted with C_1-C_4 alkoxy; or

xvi) 2-azabicyclo[2.2.2]oct-3-yl substituted in the 2-position with variable R^{28} and optionally further substituted with oxo, or optionally further substituted with one or two substituents independently selected from hydroxy, fluoro, and C_1-C_6 alkyl;

X is CH, N, or N^+-O^-;

Y is CR^{11}, N, or N^+-O^-;

Q is CR^{12}, N, or N^+-O^-;

R^4 is hydrogen, C_1-C_6 alkyl optionally substituted up to three times with fluoro, or phenyl;

R^5 is hydrogen, C_1-C_6 alkyl optionally substituted up to three times with fluoro, phenyl, -C(O)(C_1-C_6 alkyl optionally substituted up to three times with fluoro), or –SO_2(C_1-C_6 alkyl optionally substituted up to three times with fluoro);

R^6 and R^7 are independently selected from the group consisting of methyl, ethyl, and propyl;

R^8 is hydrogen or C_1-C_6 alkyl;

R^9 is C_3-C_5 cycloalkyl, sec-butyl, or –CH_2R^{13};

R^{10} is –CF_2R^{14}, -OR^{15}, -$CH_2C(O)CH_3$, -$S(O)_{1\text{-}2}R^{16}$, -$NR^{17}SO_2R^{18}$, (C_1-C_3 alkoxy)-carbonyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,1-dioxo-2,3,4,5-tetrahydroisothiazol-2-yl, or tetrazol-5-yl optionally substituted with C_1-C_3 alkyl;

R^{11} is hydrogen, chloro, isobutyl, CH_2R^{19}; CF_2R^{20}, 1,1,1-trifluoro-2-hydroxyeth-2-yl, C_2-C_4 alkenyl optionally substituted with one or two fluorine atoms, OR^{21}, $C(O)R^{22}$, N(methyl)(methylsulfonyl), N(methyl)(acetyl), pyrrolidin-2-on-1-yl, methylsulfonyl, N,N-dimethylaminosulfonyl, phenyl optionally substituted with one or two substituents selected from the group consisting of hydroxymethyl, methoxy, fluoro, and methylsulfonyl, 1,3-dioxolan-2-yl, 1,3-dithiolan-2-yl, 1,3-oxathiolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithian-2-yl, pyridinyl, thiazolyl, oxazolyl, or 1,2,4-oxadiazolyl optionally substituted with methyl;

R^{12} is hydrogen or fluoro;

R^{13} is ethynyl or cyclopropyl;

R^{14} is hydrogen or methyl;

R^{15} is difluoromethyl or methanesulfonyl;

R^{16} is C_1-C_4 alkyl, C_3-C_6 cycloalkyl, phenyl, or $-NR^{25}R^{26}$;

R^{17} is hydrogen, C_1-C_3 alkyl optionally substituted with up to 3 fluorine atoms, or C_3-C_6 cycloalkyl;

R^{18} is C_1-C_3 alkyl or C_3-C_6 cycloalkyl;

R^{19} is fluoro, hydroxy, or C_1-C_3 alkoxy;

R^{20} is hydrogen, phenyl, or furyl;

R^{21} is C_1-C_3 alkyl optionally substituted with one or two fluorine atoms;

R^{22} is C_1-C_3 alkyl, C_3-C_5 cycloalkyl, C_2-C_3 alkenyl, C_1-C_3 alkoxy, $NR^{23}R^{24}$, pyrrolidin-1-yl optionally substituted with methyl or one or two fluorine atoms, piperidin-1-yl, phenyl, pyridinyl, or furyl;

R^{23} is hydrogen or methyl;

R^{24} is methyl, ethyl, or propyl;

R^{25} is hydrogen or methyl;

R^{26} is methyl; or

R^{25} and R^{26} taken together with the nitrogen atom to which they are attached form a pyrrolidine or piperidine ring;

R^{28} is hydrogen or a nitrogen protecting group;

R^{29} is hydrogen or C_1-C_6 alkyl;

R^{30} is hydrogen or C_1-C_6 alkyl;

R^{29} and R^{30} taken together with the nitrogen to which they are attached form a C_3-C_6 cycloalkyl ring;

R^{31} is hydrogen, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, or phenyl optionally monosubstituted with C_1-C_6 alkyl;

R^{32} is hydrogen, R^{33}, or $-(CH_2)_{0\text{-}2}$-OR^{33};

R^{33} is C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2-C_6 alkenyl, C_2-C_6 alkynyl, or $-(CH_2)_{0\text{-}3}$-R^{34};

R^{34} is C_3-C_7 cycloalkyl or phenyl each optionally substituted with one or two substitutents independently selected from the group consisting of halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, thienyl optionally substituted with halo, benzothienyl optionally substituted with halo, thiazolyl optionally substituted with C_1-C_4 alkyl, or adamantyl;

R^{35} is $-(CH_2)_{0-6}-R^{34}$,$-C(O)-(CH_2)_{0-6}-R^{34}$, $-C(O)-(C_1-C_{10}$ alkyl), $-C(O)-(C_1-C_4$ alkoxy optionally substituted with phenyl), C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, C_2-C_{10} alkenyl, or C_2-C_{10} alkynyl;

R^{36} and R^{37} are both hydrogen or, taken together with the carbon atom to which they are attached form a carbonyl group;

R^{38} is hydrogen or an oxygen protecting group;

R^{39} and R^{40} are independently selected from methyl, ethyl, or propyl; or an acid addition salt thereof provided that no more than one of X, Y, and Q may be N or N^+-O^-.

Claim 9 (new): A method for the inhibition of production of A-β peptide comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.

Claim 10 (new): A method of inhibiting BACE in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.